Role of plasminogen/plasmin system components and matrix metalloproteases in retinal artery occlusion following cardiac surgery

Authors

  • L.V. Natrus Bogomolets National Medical University, Ministry of Health of Ukraine
  • N.Ia. Kovalchuk SI “Heart Institute of the Ministry of Health of Ukraine” https://orcid.org/0009-0005-6548-3095
  • I.S. Tanasiichuk Bogomolets National Medical University, Ministry of Health of Ukraine
  • Iu.O. Panchenko Schupyk National Healthcare University of Ukraine, Ministry of Health of Ukraine

DOI:

https://doi.org/10.31288/oftalmolzh202463339

Keywords:

retina, retinal artery occlusion, valvular heart disease, cardiosurgical interventions, plasminogen/plasmin system, MMP-9

Abstract

Purpose: To assess the impact of plasminogen/plasmin system components and matrix metalloproteases (MMPs) on the development of retinal artery occlusion (RAO) after cardiac surgery for valvular heart disease (VHD).
Material and Methods: Seventy three patients who underwent cardiac surgery for VHD were included in the study. Of these, 23 patients older than 60 years who had conventional-access mechanical prosthetic valve replacement with cardiopulmonary bypass were stratified into the group of high risk (HR) for RAO. Ten HR patients developed branch or central RAO. The low-risk (LR) group comprised 50 patients younger than 60 years who had valvuloplasty via a minimally invasive approach or the femoral artery using a biological implant. The control group comprised 15 patients who had no cardiac disease. Coagulogram indices and D-dimer were measured. Enzyme-linked immunosorbent assay kits were used to determine plasma plasminogen activator inhibitor (PAI)-1, plasmin-α2-antiplasmin complex (PAP), and tissue inhibitor of MMP-3 (TIMP-3) levels. MMP levels were determined by enzyme gelatin zymography.
Results: The PAI-1 levels were three times higher in HR groups than in controls. Mean PAI-1 levels were almost identical in patients who developed RAO and patients who did not develop RAO. The level of PAP in HR patients was 4-6 times lower than in the control group. MMP-9 activity was 2.5-fold lower in HR group patients who did not develop RAO than in those who developed RAO. In the latter patients, the level of plasma TIMP-3 was 2.3-fold lower than in controls. Mean plasma TIMP-3 level was almost identical in patients who did not develop RAO and LR patients. The mean plasma D-dimer level was the highest in patients who developed RAO; this was 16-fold higher than in the control group, and 11-fold higher than in patients who did not develop RAO.
Conclusion: High functional activity of plasmin and proteolytic MMP-9 activity are the major factors of the fibrinolytic system which cause the development of RAO in patients undergoing cardiac surgery. Regulators of plasminogen/plasmin activation (such as PAI-1 and PAP) and TIMP-3 do not play a substantial role in the development of complications in the form of RAO.

References

Aluru JS, Barsouk A, Saginala K, Rawla P, Barsouk A. Valvular Heart Disease Epidemiology. Med Sci (Basel). 2022 Jun 15;10(2):32. https://doi.org/10.3390/medsci10020032

Maganti K, Rigolin VH, Sarano ME, Bonow EO. Valvular Heart Disease: Diag-nosis and Management. Mayo Clin Proc. 2010 May;85(5):483-500. https://doi.org/10.4065/mcp.2009.0706

Rubin DS, Matsumoto MM, Moss HE, Joslin CE, Tung A, Roth S. Ischemic Optic Neuropathy in Cardiac Surgery: Incidence and Risk Factors in the United States from the National Inpatient Sample 1998 to 2013. Anesthesiology. 2017 May;126(5):810-821. https://doi.org/10.1097/ALN.0000000000001533

Panchenko YuO, Kovalchuk NYa. [Risk factors for the development of retinal artery occlusions after cardiac surgery for valvular heart disease]. Clinical Ophthalmology. 2023;11(3):31-5. Ukrainian. https://doi.org/10.22141/2309-8147.11.3.2023.340

Lijnen RH, Van B H, Lupu F, Moons L, Carmeliet P, and Collen D. Function of the Plasminogen/Plasmin and Matrix Metalloproteinase Systems After Vascular Injury in Mice With Targeted Inactivation of Fibrinolytic System Genes. Arterioscler Thromb Vasc Biol. 1998;18(7): 1035-45. https://doi.org/10.1161/01.ATV.18.7.1035

Leebeek FW, Kluft C, Knot EA, et al. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin. J Am Coll Cardiol. 1990;15(6):1212-20. https://doi.org/10.1016/S0735-1097(10)80003-8

Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S. Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1. PLoS ONE. 2011;6(11):e26762. https://doi.org/10.1371/journal.pone.0026762

Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010 Oct;28(5):e72-91. https://doi.org/10.1111/j.1755-5922.2010.00171.x

Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes. 1997; 46: 860-7. https://doi.org/10.2337/diab.46.5.860

Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 2007; 12: 2957-66. https://doi.org/10.2741/2285

Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005 Jan;38(1):73-83. https://doi.org/10.2144/05381RV01

Sillen M, Declerck PJ. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target? Int J Mol Sci. 2021 Mar 8;22(5):2721. https://doi.org/10.3390/ijms22052721

Weisberg AD, Albornoz F, Griffin JP, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol. 2005;25: 365-71. https://doi.org/10.1161/01.ATV.0000152356.85791.52

Reed GL, Houng AK, Singh S, Wang D. α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke. Semin Thromb Hemost. 2017 Mar;43(2):191-9. https://doi.org/10.1055/s-0036-1585077

Ho CH, Wang SP. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction. Thromb Res. 1990 May 1;58(3):331-41. https://doi.org/10.1016/0049-3848(90)90102-I

Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1104-17. https://doi.org/10.1161/hq0701.093685

Singh S, Houng AK, Wang D, Reed GL. Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. J Thromb Haemost. 2016 Sep;14(9):1822-32. https://doi.org/10.1111/jth.13390

Rosell A, Cuadrado E, Ortega-Aznar A, et al. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39(4):1121-6. https://doi.org/10.1161/STROKEAHA.107.500868

Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol. 2008;8(1):82-9. https://doi.org/10.1016/j.coph.2007.12.001

Cooper JA, Lo SK, Malik AB. Fibrin is a determinant of neutrophil sequestration in the lung. Circ Res. 1988;63(4):735-741. https://doi.org/10.1161/01.RES.63.4.735

Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol. 2001;21(12):2093-8. https://doi.org/10.1161/hq1201.100255

Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12(4):441-5. https://doi.org/10.1038/nm1387

Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke. 2002;33(11):2711-7. https://doi.org/10.1161/01.STR.0000033932.34467.97

Lafleur MA, Forsyth PA, Atkinson SJ, Murphy G, Edwards DR. Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity. Biochem Biophys Res Commun. 2001;282:463-73. https://doi.org/10.1006/bbrc.2001.4596

Published

2025-01-06

How to Cite

1.
Natrus L, Kovalchuk N, Tanasiichuk I, Panchenko I. Role of plasminogen/plasmin system components and matrix metalloproteases in retinal artery occlusion following cardiac surgery. J.ophthalmol. (Ukraine) [Internet]. 2025 Jan. 6 [cited 2025 Jan. 8];(6):33-9. Available from: https://ua.ozhurnal.com/index.php/files/article/view/217

Issue

Section

Clinical Ophthalmology